RA stands for rheumatoid arthritis, a chronic autoimmune disease in which your immune system mistakenly attacks the lining of your joints. Unlike osteoarthritis, which results from wear and tear, RA is driven by inflammation that can damage joints and, over time, affect organs like the heart and lungs. It affects roughly 209 out of every 100,000 people worldwide, with women diagnosed significantly more often than men.
How RA Differs From Other Arthritis
The hallmark of rheumatoid arthritis is symmetrical joint involvement. If your left wrist is swollen and stiff, your right wrist is likely affected too. This pattern helps distinguish RA from other forms of arthritis, though early in the disease, when only a few joints are involved, the symmetry may not be obvious yet.
Morning stiffness is another defining feature. While many types of arthritis cause some stiffness after rest, RA typically produces stiffness lasting more than one hour, often several hours. Osteoarthritis stiffness, by comparison, usually eases within 20 to 30 minutes of moving around.
What Happens Inside Your Joints
Every joint is lined with a thin membrane called the synovium, which produces fluid to keep the joint lubricated. In RA, immune cells infiltrate this membrane and trigger chronic inflammation. The inflamed tissue thickens into an aggressive layer called pannus, which grows directly into cartilage and bone like a slow-moving invasion.
Three processes drive the damage. First, the inflamed synovial tissue itself physically invades the joint. Second, it releases enzymes that break down the cartilage’s structural fibers, the way acid eats through fabric. Third, specialized bone-dissolving cells become overactive, eroding the bone underneath. These three processes feed each other through inflammatory signaling molecules, which is why early treatment matters so much: once the cycle is established, joint destruction accelerates.
Common Symptoms
RA most often starts in the small joints of the hands and feet, particularly the knuckles and the joints at the base of the toes. Over time it can spread to the wrists, elbows, shoulders, knees, and ankles. Affected joints feel warm, swollen, and tender. Many people describe a “boggy” feeling when pressing on the joint, distinct from the hard, bony swelling of osteoarthritis.
Fatigue is one of the most underestimated symptoms. The systemic inflammation that drives RA also causes deep, persistent tiredness that doesn’t improve much with rest. Low-grade fevers and unintentional weight loss can occur during flares as well.
Effects Beyond the Joints
RA is a systemic disease, meaning it can reach well beyond your joints. The most common non-joint complications involve the heart and lungs.
- Heart: About 15% of RA patients develop pericarditis, inflammation of the sac surrounding the heart. Electrocardiograms reveal some degree of pericardial involvement in 20% to 50% of patients, even when symptoms like chest pain or shortness of breath are mild or absent.
- Lungs: Pulmonary complications occur in an estimated 60% to 80% of RA patients over time. One study found that roughly half of RA patients showed signs of interstitial lung disease on imaging, though only about 10% had noticeable symptoms like a persistent cough or breathlessness during exercise. Interstitial lung disease accounts for 10% to 20% of RA-related deaths.
- Other organs: RA can also affect the kidneys, eyes (causing dryness or inflammation), skin (firm lumps called rheumatoid nodules), and nervous system.
Risk Factors
Genetics play the biggest role. The strongest known genetic risk factor is a specific variation in the HLA-DRB1 gene, sometimes called the “shared epitope.” Carrying this gene variant doesn’t guarantee you’ll develop RA, but it substantially increases susceptibility, particularly for the antibody-positive form of the disease.
Smoking is the most important environmental trigger. It independently raises RA risk, and in people who also carry the HLA-DRB1 shared epitope, the two risk factors interact powerfully, multiplying the odds well beyond what either factor would cause alone. This gene-environment interaction is especially strong in people who test positive for both rheumatoid factor and anti-CCP antibodies. Quitting smoking reduces the risk, though the elevated risk can linger for years after stopping.
Other risk factors include female sex, age (onset peaks between 30 and 60), obesity, and a family history of autoimmune disease.
How RA Is Diagnosed
There is no single test that confirms RA. Diagnosis relies on a combination of joint symptoms, blood work, symptom duration, and markers of inflammation.
Two blood tests are central. Rheumatoid factor (RF) is the older test, with a specificity around 85%, meaning 15% of positive results are false alarms. Anti-CCP antibodies are more precise, with specificity of 95% to 96%, making a positive result a strong signal. However, anti-CCP sensitivity ranges from 53% to 71%, so a negative result doesn’t rule RA out. Some people have what’s called seronegative RA, where both RF and anti-CCP come back negative but the disease is still present.
Doctors also check levels of inflammation markers in the blood and examine which joints are affected and for how long. Under the current classification system, a score is tallied across four categories: joint involvement, blood antibodies, how long symptoms have lasted (with six weeks as a key threshold), and inflammation levels. A high enough combined score supports the diagnosis.
Treatment Approach
The goal of RA treatment is remission, or as close to it as possible. Treatment has transformed dramatically over the past two decades, and most people diagnosed today have far better outcomes than previous generations.
The first-line treatment for moderate to high disease activity is methotrexate, taken once a week as a pill or injection. Current guidelines strongly recommend starting with methotrexate alone rather than jumping to more advanced drugs, because many patients reach their treatment goal on methotrexate by itself. It works by dialing down the overactive immune response that drives joint destruction. Side effects can include nausea and fatigue, and your doctor will monitor liver function with periodic blood tests.
If methotrexate alone isn’t enough after a few months, the next step is typically adding a biologic medication. These are injectable or infused drugs that target specific parts of the immune system. The most common class blocks a protein called TNF, a key driver of inflammation. Other biologics target different immune pathways. A newer category of oral medications called JAK inhibitors offers another option for people who don’t respond to or can’t tolerate other treatments.
The “treat to target” strategy means your treatment is adjusted every few months until you reach low disease activity or remission. This aggressive, goal-oriented approach has significantly improved long-term outcomes.
Diet and Lifestyle
Diet won’t replace medication, but certain eating patterns can meaningfully reduce inflammation alongside standard treatment. The Mediterranean diet, rich in fish, olive oil, vegetables, and whole grains, has been shown in systematic reviews to significantly lower key inflammatory markers including C-reactive protein. Fish oil supplementation has also shown measurable benefits, particularly in people already taking methotrexate. One study found that adding fish oil to either a Western or anti-inflammatory diet significantly reduced CRP levels.
Regular physical activity, even gentle exercise like swimming or walking, helps preserve joint mobility and reduces fatigue. Maintaining a healthy weight matters too, since excess body fat produces its own inflammatory signals that can worsen RA activity.
Long-Term Outlook
RA is a lifelong condition, but with modern treatment, many people achieve sustained remission or very low disease activity. The earlier treatment begins, the better the chances of preventing irreversible joint damage.
That said, RA does carry a real impact on life expectancy. Studies consistently show that people with RA have a mortality rate roughly 40% to 57% higher than the general population, driven largely by cardiovascular disease. A 20-year follow-up from Australia found mortality risk grew over time, with a standardized mortality ratio of 1.49 after two decades. The good news is that timely diagnosis and effective use of modern medications have been shown to significantly narrow that gap. Keeping inflammation well controlled is the single most important thing you can do for both your joints and your overall health.